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Objectives: Brachiobasilic arteriovenous fistulas (BBAVF) can be performed in one or two stages. We compared
primary failure rates, as well as primary and secondary patency rates of one- and two-stage BBAVF at two
institutions.
Methods: Patients undergoing one- and two-stage BBAVF at two institutions were compared retrospectively with
respect to age, sex, body mass index, use of preoperative venous duplex ultrasound, diabetes, hypertension, and cause
of end-stage renal disease. Categorical variables were compared using chi-square and Fisher’s exact test, whereas the
Wilcoxon rank-sum test was used to compare continuous variables. Patency rates were assessed using the Kaplan-
Meier survival analysis and the Cox proportional hazards model with propensity analysis to determine hazard ratios.
Results:Ninety patients (60 one-stage and 30 two-stage) were identified. Mean follow-up was 14.2 months and the mean
time interval between the first and second stage was 11.2 weeks. Although no significant difference in early failure existed
(one-stage, 22.9% vs two-stage, 9.1%; P .20), the two-stage BBAVF showed significantly improved primary functional
patency at 1 year at 88% vs 61% (P  .047) (hazard ratio, 0.2 (95% confidence interval [CI], .04-.80; P  .03). Patency
for one-stage BBAVF markedly decreased to 34% at 2 years compared with 88% for the two-stage procedure (P  .047).
Median primary functional patency for one-stage BBAVF was 31 weeks (interquartile range [IQR], 11-54) vs 79 weeks
(IQR, 29-131 weeks) for the two-stage procedure, respectively (P  .0015). Two-year secondary functional patency for
one- and two-stage procedures were 41% and 94%, respectively (P  .015).
Conclusions: Primary and secondary patency at 1 and 2 years as well as functional patency is improved with the two-stage
BBAVF when compared with the one-stage procedure. Lower primary failure rates prior to dialysis with the two-stage
procedure approached, but did not reach statistical significance. While reasons for these finding are unclear, certain
technical aspects of the procedure may play a role. ( J Vasc Surg 2011;53:1632-9.)
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tThe National Kidney Foundation currently recom-
mends placement of a brachial artery–basilic vein arterio-
venous fistula (BBAVF) prior to placement of a prosthetic
graft in patients who are not candidates for a radial or
brachial artery to cephalic vein arteriovenous fistula
(AVF).1 The BBAVF, like other native AVF, appears to
have a higher patency rate and lower incidence of throm-
bosis and infection when compared with prosthetic arterio-
venous grafts (AVG).
While the BBAVF is an attractive conduit for hemodialy-
sis, it is debated whether the BBAVF should be performed in
one or two stages. To date, limited and conflicting data exist
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1632egarding failure, primary patency, and secondary patency
ates of one- and two-stage procedures.2-9
Both the one- and two-stage procedures have advantages
nd disadvantages. One obvious benefit of the one-stage
rocedure is the need for only one operation, with a potential
or earlier functional patency. In a patient who is already on
ialysis, this in turn may lead to a shorter duration of tempo-
ary venous catheter use and prevent its attendant complica-
ions such as catheter-related bacteremia, central venous ste-
osis, and malfunction. A prior small randomized study
howed a significantly higher rate of primary failure with
ne-stage BBAVF.2 One conceivable advantage of a two-
tage procedure is the ease of mobilization of a larger “arteri-
lized,” thicker-walled vein, rendering it less susceptible to
orque and devascularization during mobilization.10 In addi-
ion, with the two-stage procedure, if early failure is detected,
he superficialization procedure is not performed and the
atientmay be spared an unnecessary long incision in the arm.
he primary disadvantages of the two-stage procedure are the
eed for two operations leading to additional anesthetic risk,
s well as potential delay in permanent access. This may result
n prolonged central venous catheter use during the period
etween the two procedures. These risks can be minimized
ith early referral. The purpose of our study was to compare
rimary failure rates, as well as primary, secondary, and func-
ional patency rates of one vs two-stage BBAVF performed at
wo institutions.
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Design and patient data collection
The study was approved by the Institutional Review
Board of Harbor-UCLA and the Stanford Human Subjects
Research Office. We retrospectively identified all patients
who underwent fistula placement at Stanford University
Medical Center and Harbor-UCLA between January 1,
2001 and December 31, 2010. Patients who underwent
BBAVF were subgrouped according to one-stage or two-
stage BBAVF. The patients were consecutive and the sur-
geons were solely responsible for vascular access at both
institutions. In accordance with NKF KDOQI (National
Kidney Foundation Kidney Disease Outcomes Quality Ini-
tiative) guidelines, the goal is fistula first, with preferred
access of choice being radial-cephalic, followed by brachial-
cephalic, followed by BBAVF prior to AVG.Minimum vein
threshold at all sites for AVF is 2.5 mm as determined by
preoperative duplex or intraoperative assessment with cor-
onary dilators.
BBAVF was the planned procedure in patients with
vein mapping with inadequate upper arm and forearm
cephalic vessels secondary to previous dialysis, trauma, or
insufficient diameter. An unplanned BBAVF was placed in
patients who were unexpectedly found to have an upper
arm cephalic vein 2.5 mm in diameter and a basilic 2.5
mm at the time of surgery. Four two-stage operations had
documented previous AV access procedures on the same
side. Three one-stage operations had documented prior AV
access procedures on the same side.
Patient demographics included age, gender, and body
mass index (BMI), comorbid conditions (history of hyper-
tension, diabetes, and cause of end-stage renal disease),
preoperative hemodialysis, and use of preoperative duplex
ultrasound for vein mapping (Table I). Data from operative
reports, clinic visits, dialysis center visits, and extended
medical record were evaluated to collect dates of operation,
fistula maturation, first successful dialysis, postoperative
complications or revisions, and last known date of patency.
Postoperative data were used to derive primary patency,
secondary patency, and functional patency (see “Definition
of Variables” section). All patients that underwent kidney
transplantation or never required dialysis were censored for
patency analysis, as was death.
To address possible selection bias, propensity scores
Table I. Demographics and comorbidities
One-stage
BBAVF (n  60)
Two-stage
BBAVF (n  30) P value
Median age 63 (45, 74) 58 (48, 66) .20
Female 37% 56% .11
BMI (median) 25 (22, 29) 28 (25, 33) .02
Preop duplex 75% 63% .32
Diabetes 44% 77% .002
Hypertension 88% 97% .25
BBAVF, Brachiobasilic arteriovenous fistulas; BMI, body mass index.were used, which represent the probability of having a pwo-stage procedure for each observation in the sample.
he following variables: age, gender, preoperative hemodi-
lysis, diabetes, and BMI were able to be included in a
ultivariable model generating the propensity of undergo-
ng the two-stage procedure. This propensity score was
ubsequently used to adjust for potential bias in interven-
ion assignment by including the score as an independent
ovariate in a second multivariable logistic regression anal-
sis predicting outcome (hazard ratio for patency).
efinition of variables
All variableswere defined in accordancewith theSocietyof
ascular Surgery (SVS), the American Association of Vascular
urgery, and recommendations from NKF KDOQI.1,11,12 Pri-
ary patency was defined as the interval from the time of access
lacement to thrombosis or any intervention to reestablish
ow. Secondary patency was defined as the time interval from
ccess placement until site abandonment. SVS reporting stan-
ards specify the beginning of functional patency to begin
hen “able to deliver a flow rate of 350 to 400 mL/min
ithout access recirculation tomaintain a treatment time less
han 4 hours.” We modified the definition for this study
lightly because of difficulty obtaining flow rates during
etrospective chart review. We defined the beginning of
unctional patency at first successful two-needle dialysis
ith a treatment time of 4 hours.
Early failure of the fistula was defined as absence of a
ruit and thrill with absence of flow on duplex ultrasound
can or nonmaturation. Patients with functioning fistulas
ho underwent endovascular procedures to improve flow
assisted primary patency) were reported as maintaining
rimary patency in this study.
Early (30 day) complications as well as major and
inor30 day complications of infection, steal syndrome,
neurysm, seroma/hematoma, nonmaturation, stenosis,
nd thrombosis were predefined and recorded at the time
f retrospective chart review based on clinic and inpatient
ocumentation, similar to previous studies.3,10 Infection
as recorded based on chart review for signs and/or symp-
oms, including purulent drainage, cellulitis, fevers, and
levated white blood cell count. Steal syndrome was de-
ned by signs or symptoms of hand ischemia. Seroma/
ematomawas recorded if a fluid collection with or without
rainage was documented in the chart. Nonmaturation was
ecorded if a fistula failed to increase in size (if duplex
ltrasound was used) or developed a thrill within 6 weeks.
tenosis and thrombosis were recorded if confirmed by
linical examination, venography, or duplex ultrasound.
escription of surgical technique
One-stage BBAVF procedure. Creation of the one-
tage fistula began with a 2-cm transverse incision just distal
o the antecubital crease to expose the brachial artery and
asilic vein. A continuous longitudinal incision was then
ade proximal to the elbow on the medial side of the upper
rm to dissect the basilic vein. The basilic vein tributaries
ere ligated. The basilic vein was transected as distal as
ossible and care was taken to preserve the medial antebra-
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June 20111634 Reynolds et alchial cutaneous nerve. The vein was gently dilated with
dilute heparinized saline or papaverine. The vein was trans-
posed to the anterior arm beneath a subcutaneous pocket
(90% cases) or with the use of a tunneling device (10%
cases) with care not to kink, twist, or traumatize the vein.
Systemic heparin was given prior to arteriotomy and an
end-to-side basilic vein to brachial artery anastomosis was
performed using running 6-0 prolene suture. If a lateral
skin flap was chosen, a subcutaneous pocket was first
formed to place the fistula on the anterior surface of the
upper arm. The underlying subcutaneous tissue was then
secured to the overlying skin flap using 3-0 vicryl suture to
keep the fistula in a lateral position.
Two-stage BBAVF procedure. In the two-stage pro-
cedure, the basilic vein and brachial artery are exposed via a
similar 2-cm incision just distal to the antecubital crease. An
end-to-side basilic vein to brachial artery anastomosis was
performed using running 6-0 prolene suture in the same
manner described abovewithout initial superficialization. Any
venous tributaries accessible from the incision were ligated.
Following a variable time period of 30 to 90 days from the
initial operation, the “arterialized” basilic vein was then mo-
bilized in a second stage. Early in our experience, we waited
closer to 90 days for the second stage, but as we gained more
experience, we realized that the second stage can be per-
formed as early as 30 days after the initial surgery provided a
good thrill was present. We have not utilized interim duplex
scanning, although in theory, assessing flow and diameter of
the fistula may be of benefit. The second stage was performed
by transposition under a lateral skin flap rather than tunneling
in 90% of cases and performed in the same fashion as above.
The majority of one-stage procedures during the first half of
the study period were tunneled, while over 50% of the proce-
dures during the second half utilized the lateral skin flap. Both
one- and two-stage procedures were performed under local
anesthesia or regional block.
Statistical analysis
Data were compiled onto an Excel spreadsheet (Mi-
crosoft Excel; Microsoft Corporation, Redmond, Wash)
and translated into a native SAS format usingDBMS/Copy
(Dataflux Corporation, Cary, NC). Analyses were con-
ducted using either SPSS (SPSS Inc, Chicago, Ill) or SAS
version 9.2 (SAS Institute, Cary, NC). Descriptive statistics
were calculated for all variables. Categorical variables were
compared using 2 and Fisher’s exact tests. Continuous
variables such as patency times and functional patency times
were not normally distributed and were therefore com-
pared using the nonparametric Wilcoxon rank-sum test and
are reported as medians with interquartile ranges (IQRs).
Primary and secondary patencies were estimated with the
use of the Kaplan–Meier method. Cox proportional haz-
ards models, stratified according to presence of diabetes
and BMI, were used to estimate hazard ratios and to test for
significance of the timing of events. Data from patients who
had patent fistulas at the last follow-up (March 12, 2010)
were censored on that date. Descriptive statistics were used
for complication events. All reported P values are two- fided, and a P value of .05 was considered statistically
ignificant.
ESULTS
Ninety (60 one-stage and 30 two-stage) were identi-
ed. During this time period, all BBAVFs performed at one
nstitution were one-stage procedures. The second institu-
ion performed both one- and two-stage procedures, with
ore one-stage procedures performed in the first half of the
tudy period and more two-stage during the latter half.
atients undergoing two-stage procedures had a higher
MI and were more often diabetic as seen in Table I. For
wo-stage procedures, the mean time interval between the
rst and second stage was 11.2 weeks. Median time to first
se was 12.3 weeks for one-stage procedures (interquartile
ange [IQR], 9.8-17.6 weeks) and 19.3 weeks for two-
tage procedures (IQR, 14.3-24 weeks) (P  .007). The
ean follow-up period was 14.2 months.
There was no difference in early failure between the two
roups even when adjusted for propensity scores as seen in
able II. A single patient did not undergo a second stage
ecause the fistula failed to mature with no palpable thrill at
ollow-up. A duplex scan showed the fistula to be patent
ut remained diffusely small in diameter. This patient was
ncluded in analysis as a “primary failure” and subsequently
nderwent placement of a brachial-brachial fistula.
Overall, the primary patency rate for all BBAVF was 80%
t 1 year and 50.7% at 2 years. The overall secondary patency
ate was 84.3% at 1 year and 60.7% at 2 years. Three working
stulas in the two-stage group and six working fistulas in the
ne-stage group required procedures to maintain assisted
rimary patency. All of these patients underwent angioplasty
or anastomotic or para-anastomotic stenoses with the excep-
ion of a two-stage fistula that underwent open excision of a
ingle pseudoaneurysm with reanastomosis.
Primary, secondary, and functional patency rates are
hown in Table II. Primary functional patency and secondary
able II. Primary failure, primary patency, and secondary
atency rates for one-stage vs two-stage BBAVF
One-stage
BBAVF
(n  60)
Two-stage
BBAVF
(n  30) P value
rimary failure 22.9% (11) 9.1% (2) .20
rimary patency
One year 78% 84% .046
Two year 34% 84%
econdary patency
One year 82% 89% .01
Two year 41% 89%
rimary functional patency
One year 61% 88% .047
Two year 34% 88%
econdary functional patency
One year 80% 94% .015
Two year 41% 94%
BAVF, Brachiobasilic arteriovenous fistulas.unctional patency for both procedures is depicted in Kaplan–
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Volume 53, Number 6 Reynolds et al 1635Meier graphs seen in Figs 1 and 2, respectively. Using propor-
tional hazards modeling incorporating propensity scores, the
overall primary patency was significantly higher in the two-
stageBBAVF (hazard ratio, 0.2; 95% confidence interval [CI],
.05-.80; P  .02) as seen in Table III. The median primary
patency for one- and two-stage BBAVF was 41 (IQR, 21-64
weeks) and 92 weeks (IQR, 50-126 weeks), respectively (P
.0002). Median secondary patency was 44 weeks (IQR, 21-
66) and92weeks (60 to126) (P .0003).Median functional
primary patency after initial use for one- and two-stage
BBAVF was 31 (IQR, 11-54 weeks) and 79 weeks (IQR,
29-131 weeks), respectively (P .0015).
There was no difference in 30-day complication rates of
primary failure, seroma, and infection at 27.1% for one-
stage procedures and 17.5% for two-stage procedures (P
.62) as seen in Table IV. Major complications leading to
loss of fistula or intervention over 30 days were primarily
related to thrombosis, stenosis, and steal syndrome and led
to failure in 66% of one-stage fistulas and 16.7% in the
Fig 1. Kaplan–Meier curve depicting primary functiona
venous fistulas (BBAVF) (Dashed line indicates standardtwo-stage group as seen in the patency analyses (P .046). pISCUSSION
The study provides further patency data on BBAVF,
hich has become an increasingly important option in an
ra when patients are surviving for decades with chronic
enal failure. The present study compared 60 one-stage and
0 two-stage BBAVF, using data from two institutions.
arly failure rates were greater for one-stage procedures at
2.9% vs 9.1%, although this difference did not reach
tatistical significance. Multivariable proportional hazards
odels with adjustment for propensity scores show im-
roved primary, secondary, and functional patency rates
ith the two-stage operation. These findings suggest that
he two-stage approach is preferable.
We suspect that patency for one-stage procedure is
ecreased due to various reasons. Extensive mobilization
nd tunneling of a nonmatured, thin-walled basilic vein
ay render the vein more prone to ischemia, injury, and
inking that may lead to subsequent stenosis and thrombo-
is. We hypothesized that primary failure rates and early
ncy for one-stage and two-stage brachiobasilic arterio-
10%).l pateatency rates would be most adversely affected. While
l
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June 20111636 Reynolds et alprimary failure rate was markedly diminished for the two-
stage BBAVF, the difference did not reach statistical signif-
icance likely secondary to type II error (power 46%).
Achieving 80% power to detect a difference between the
groups would require sample sizes of 122 and 60.
Although ischemic injury secondary to rough handling
of the vein would seem to present with failure within the
first year, a recent comparison between endoscopic and
open saphenous vein harvesting for coronary artery bypass
Fig 2. Kaplan–Meier curve depicting secondary func
arteriovenous fistulas (BBAVF) (Dashed line indicates sta
Table III. Multivariable proportional hazards models with
Multivariable proportional hazards models
adjusted for propensity scores
Hazard
Primary patency
Primary functional patency
Secondary patency
Secondary functional patency
BBAVF, Brachiobasilic arteriovenous fistulas.grafting suggests that results of injury to the vein may take songer to manifest. Endoscopic harvesting is thought to
ause more ischemic injury due to the nature of the dissec-
ion and was shown to be associated with higher vein graft
ailure compared with open vein harvesting. Interestingly,
hese vein grafts failed at 12 to 18 months, rather than
ess than 12 months as expected. In addition, higher
ates of heart attack and death were reported at 3 years
fter surgery.13
Patency data for BBAVF in the literature have demon-
l patency for one-stage and two-stage brachiobasilic
d error 10%).
stment for propensity scores
o for two-stage
AVF 95% CI P value
2 0.05-0.8 .02
2 0.04-0.8 .03
12 0.02-0.7 .02
11 0.01-0.97 .046tionaadju
rati
BB
0.
0.
0.
0.trated a wide variability. Primary failure rates have been
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Volume 53, Number 6 Reynolds et al 1637reported to vary from 6% to 23%.4 The reported mean
primary patencies for BBAVF, regardless of technique, vary
from 35% to 92% at 1 year, with an average patency of 72%,
whereas the reported mean secondary patencies vary from
55% to 96%, with an average of 75%.3,14 At 2 years, primary
and secondary patency drop to 60.4% (28%-86%) and
67.5% (52%-86%), respectively.14 The wide range of pa-
tency rates may be related to variability in technique, re-
porting definitions, including patency and functional pa-
tency, and lack of early thrombosis data. Transposition of
the basilic vein for ease of hemodialysis access to a more
antero-lateral position in the upper arm is widely accepted
as optimal and is the goal in both one- and two-stage
procedures and was performed for all patients in this study.
Functional patency may be a better tool for reporting
success of hemodialysis access when comparing staged opera-
tions. This measure uses the date of successful dialysis rather
than the date of surgery and effectively eliminates the variable
time period between the stages in a two-stage operation that is
included in traditional patency analyses. A previous study
reports overall primary functional patency at 45.3% at 1 year
and 40.0% at 2 years.15 Our study reports higher primary
functional patency overall; however, a marked drop in func-
tional patency for the one-stage procedure is encountered.
The same study reports secondary functional patency of
BBAVF at 53.6% at 1 year and 50.9% at 2 years.15 Our study
reports higher secondary functional patency overall, with a
marked discrepancy in 1- and 2-year patency rates between
the two techniques. There were several cases reported in
the one-stage group of difficulty with tunneling or creation
of the lateral pocket that led to twisting of the fistula. This
was not encountered during the two-stage operation, likely
because the vein had “arterialized.”
Few prior studies have directly compared one-stage
with two-stage BBAVF. The only prospective, randomized
trial looking at the two types of BBAVF formation was
conducted in 40 patients in 1998.2 Time to second stage
was markedly shorter at 2 to 4 weeks with initial angio-
Table IV. Complication rates for one-stage vs two-stage
BBAVF
One-stage
(n  60) %
Two-stage
(n  30) % P value
Complication 30 day 27.1% 17.5% .62
Infection 4.2 4.2 .053
Seroma 0 4.2 NA
Primary failure 22.9 9.1 .17
Minor complication 30 day 6.3% 9.1% .54
Pseudoaneurysm 2.1 4.5 .18
AV fistula 2.1 0 NA
Hematoma 2.1 4.5 .18
Major complication 30 day 66% 16.7% .046
Stenosis 18.8 9.1 .08
Steal syndrome 2.1 4.5 .18
Thrombosis/ligation 45.1 3.1 .029
BBAVF, Brachiobasilic arteriovenous fistulas.access as early as 10 days after the second operation. Early tailure (prior to 4 weeks) was 40% for the one-stage fistulas
nd 10% for two-stage fistulas (P  .05). By the end of the
tudy period (follow-up, 6-24 months; mean, 14.8-16
onths), a statistically significant improvement in primary
atency was observed in the two-stage operation over the
ne-stage operation (80% vs 50%; P  .005). Our report
onfirms these findings, suggesting the optimal method for
BAVF creation is in two stages.
BBAVF may be a better option than prosthetic arterio-
enous grafts (AVG) in patients without suitable cephalic
pper or forearm veins. Several studies have compared
arious BBAVF with AVG.3,11-19 In particular, if the pa-
ient is already undergoing dialysis via a central venous
ermacath, one must weigh the risks of prolonged central
ein catheterization while awaiting BBAVF maturation
ith the increased complication rate associated with AVG
lacement. A previous study showed an increased rate of
hrombosis with AV graft compared with BBAVF (relative
isk, 2.6; 95% CI, 1.3-5.3).16 AVG were also found to
equire more frequent interventions (2.4 vs 0.7 per year;
 .001) and were more likely to become infected. The
maller anastomosis with AVF compared with AVG may
ontribute to a lower incidence of steal syndrome and
igh-output cardiac failure; however, this is controver-
ial.2,16 AVG and BBAVF were again compared in 2008,
howing increased early complications with BBAVF and
ncreased late thrombosis with AVG.17
Several other technical issues remain unresolved with re-
pect to BBAVF creation. One issue is the optimal timing of
uperficialization for the two-stage procedure. It is possible
hat a longer time interval between first and second stagesmay
mprove long-termpatency rates.Medicare currently does not
ave a clear coding protocol in place for the two-stage
BAVF. The applicable codes for BBAVF have global periods
f 90 days. While the optimal interval for “arterialization” is
nknown, it appears fromour study thatwaitingmore than90
ays is unnecessary and may prolong central venous catheter
se unnecessarily. Alternative coding for a planned two-stage
BAVF should be considered.
The technical aspects of the second stage, namely
hether to divide and tunnel the vein or simply move the
ndivided vein more antero-laterally by creating a skin flap,
lso needs to be addressed. The authors prefer the latter to
void ligation and reanastomosis. Finally, the role of rou-
ine duplex scanning preoperatively and after the first stage
s debated. Most vascular surgeons currently recommend
outine duplex vein mapping if a BBAVF is being contem-
lated, given the difficulty in clinical evaluation of the
essel. This allows for detection of early entry of the basilic
ein into brachial vein, a finding that makes it more difficult
o subsequently superficialize an adequate length of vein.
Themedial antebrachial cutaneous nerve innervates the
kin of the medial and anterior surfaces of the arm and
orearm as far as the wrist with up to three branches above
he elbow near the basilic vein. Injury to the nerve would
esult in sensory deficits in this region and every effort is
ade to avoid injury for this reason. On occasion, one of
hese branches may be tethered over the basilic vein and
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superficialize and transpose the vein. Unfortunately, in this
retrospective review, we were unable to gather information
regarding postoperative cutaneous sensory nerve deficits.
Our study has several limitations. The retrospective,
nonrandomized design of the study allows for institution
and physician-bias that limits interpretation of results. At
one institution, all patients underwent one-stage proce-
dures, whereas at the other, one-stage BBAVF was primar-
ily performed at the beginning of the study period, whereas
two-stage procedures were preferred during the latter half.
As such, it is conceivable that secondary patency rates may
be improved in the latter patients, given the recent trend
toward free-standing vascular access centers. It should be
noted that the primary findings in this study were the
significantly improved primary patency rates with the two-
stage procedure. This data would be unaffected by the
recent trend toward closer surveillance and intervention.
Regardless, we unfortunately did not have enough patients
to perform a subanalysis of secondary patency in the first
half to compare with the second half of the study period.
Patients in the two-stage group had a higher mean BMI
and were more likely diabetic. This may be related to geogra-
phy, as all two-stage procedures were performed in an area
with higher prevalence of these medical problems. Finally,
since most patients did not undergo preoperative vein map-
ping, data is not available on vein diameters. Less than half of
the two-stage patients received a preoperative ultrasound.
In conclusion, longer-lasting hemodialysis access im-
proves patient outcome and decreases morbidity associated
with dialysis. In accordance with clinical guidelines, it is our
policy to provide native AV access to our dialysis patients
whenever possible. Factors to consider include the caliber
of the basilic vein, ongoing dialysis, presence of a central
venous catheter, and the overall medical health of the
patient, including the patient’s anticipated life span.
BBAVF can be performed as either a one- or two-stage
procedure. There was a trend toward decreased primary
failure rates with the two-stage operation; however, this
was not statistically significant. Furthermore, our study
demonstrated significantly improved primary, secondary,
and overall functional patency for the two-stage operation.
The two-stage procedure resulted in a longer-functioning
fistula and, therefore, the authors believe it to be the
method of choice for BBAVF creation. This study provides
insight into the technical aspects of the BBAVF that may
contribute to the variable patency rates reported in the
literature. Future investigation should focus on optimal
technical considerations and long-term patency in the two-
stage procedure the relationship given the increasingly
longer lifespan in this patient population. SEFERENCES
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Dr Robert G. Scribner (Daly City, Calif). In 1971, Bill
Gore, one of the chemists who developed Teflon in the 1940s
showed to Drs Kelly and Eiseman after a day of skiing at Vail,
Colorado, a necktie made out of a new expanded type of Teflon.
Drs Kelly and Eiseman asked if it could be made into tubes and 5
years later the first prosthetic polytetrafluoroethylene (PTFE)
bridge fistula was placed. It is interesting to note that Dr Dagher,
in that same year, 1976, first reported on the basilic vein transpo-
sition fistula. Unfortunately, early failure rates were unacceptable.
Now, a third of a century later, access surgeons are constructing
more and more autogenous arteriovenous fistulas, largely due to
the dissemination of DOQI guidelines in 1997. In the paper just
presented, the authors conclude that their study demonstrates
significantly improved primary, secondary, and overall functional
patency for the two-stage operation. I have two questions and a
comment.
First, is there a subgroup of patients who would benefit from
the one-stage procedure over the two-stage procedure? Examples
might be early entry of the basilic vein into the brachial vein or
excellent quality of the basilic vein by preoperative vein mapping?
Second, in your paper you recommend that future long-term
investigations should focus on optimal technical considerations in
the two-stage procedure. In your study, all anastamoses were
performed with running 6-0 prolene. Do you think your early
failure rate and perhaps even your primary patency rate could be
improved by selective use of interrupted anastamoses?
Finally, in the paper the authors have detailed several study
limitations. It is retrospective, nonrandomized, and one of the two
institutions in the study performed only one-stage procedure. Also
preoperative vein mapping was not performed in all patients.
Despite these significant limitations, I believe you have presented
reasonable evidence for increased utilization of the two-stage
procedure.
Dr Tyler Reynolds. Thank you for those questions Dr Scrib-
ner. Our study was not powered to determine if there is a subgroup
of patients who would benefit from a one-stage operation. Al-
though it would be tempting to say that large-diameter veinsmight
benefit from a one-stage, we would not be able to recommend that
based on our present data. Your second question addresses the
technical aspects of the anastomosis. We perform all the anastomo-
ses with running 6-0 prolene suture. Selective use of interrupted
sutures may be appropriate in certain situations, although we do
not utilize it, and do not know if such an approach would have
lessened early failures. We agree that a potential weakness of the
study is that routine preoperative veinmapping was not performed.
The minimum basilic vein diameter, as determined intraopera-
tively, is 2.5 mm. We now do perform preoperative vein mapping
for all patients being assessed for a basilic vein fistula. As you
mentioned, one of the institutions performed only one-stage pro-
cedures, but after having analyzed our results, that institution has
switched to the two-stage approach as well.
t
uQuestion 1. Why would one-stage fistulas have such a drop
fter 1 year if injury is indeed due to mechanical injury to the vein?
Dr Christian deVirgilio (Torrance, Calif). We are not really
ure. However, the coronary bypass literature indicates that endo-
copic harvesting of the saphenous vein leads to a higher rate of
raft failure at 18 months compared with open harvesting. So it is
ossible that intraoperative vein injuries or vein ischemia during
he one-stage fistula has the potential of affecting patency beyond
year.
Question 2. The original DOQI guidelines set a benchmark
or fistula placement at 40% now 65% since last year. I think it
mportant to perform preoperative vein mapping on every AV
ccess patient. The first choice obviously is the wrist, the second is
he brachial-cephalic. The latest version of KDOQI now states that
rachial-basilic vein transposition is superior to graft. The other
ssue is selective choosing whether to do one- vs two-stage trans-
osition based on vein size. In our institution, if the vein is 4 mm
r larger, we use a one-stage technique, if between 2 and 4 mm we
se a two-stage technique.We also use an inversion technique. Has
nversion technique been considered in your two institutions?
lso, one of the best indicators of your overall dialysis access
rogram is fistula prevalence. Our approach results in 70% fistula
ate consistently over the last 4 years.
Dr deVirgilio. At Harbor-UCLA, our fistula rate is 85%. We
ave a focus on trying to create fistulas in the vast majority of our
atients. As far as basilic vein diameter is concerned, further studies
ould be needed to see if the patency rates for one-stage proce-
ures are just as good as two stages for basilic veins 4 mm. But
ntil then, our approach is to routinely use a two-stage procedure
egardless of vein diameter. A larger vein might be less prone to
njury, but it may still be at higher risk of kinking during a
ne-stage procedure. In the interest of time, we have time for only
ne more question.
Question 3. One comment, the two-stage does limit the
orbidity of a long incision in a patient that may fail prior to use
or the second stage). My question is related to the definitions of
atency. It is very difficult in a retrospective study to determine
hen a fistula became patent if you define that by cannulation. Do
ou define patency by two-needle cannulation of or by number of
ialysis successions or simply use of the fistula?
Dr Reynolds. We defined functional patency as the ability to
uccessfully perform complete dialysis via two-needle cannulation.
his is clarified in the Methods section. Clearly, patency is always
ifficult to reliably assess retrospectively at any institution. We rely
n clinic visits and local dialysis center records to monitor our
ialysis access patients.
Question 4.My question is regarding cannulation of a trans-
osed vein under a transposed flap. How do you place vein lateral
n your pocket and ensure that vein remains lateral?
Dr deVirgilio. We use a series of 6-0 prolene tacking sutures
o secure the vein at several points to subcutaneous tissue just
nder the skin. This seems to keep the vein from moving.
